Amsterdam, North Holland, Netherlands
Highly accomplished and results-driven international biotechnology executive with 25+ years of experience driving clinical and commercial success in the biotechnology industry. Proven ability to build and empower high-performing teams, translating complex innovative technologies into market-leading products. Extensive C-suite experience (20+ years) with a strong track record in deal negotiation and closure, securing over 100 partnerships with diverse stakeholders including pharma, academia, distributors, and governments. Instrumental in raising over $300 million in venture and public capital financing in both Europe and the US. Currently CEO of a NASDAQ-listed company with a deep understanding of public markets, M&A, company building, including the successful co-founding and sale of a molecular diagnostics company. Holds a Master's degree in Molecular Sciences.
• Leader of all global medical, clinical, reimbursement and business development activities, • Developed and implemented clinical trial strategy, contracted 200+ hospitals globally participate in 5 prospective Agendia designed and managed clinical trials to grow market share in a 1 billion dollar market • Developed global medical product strategies for clinical adoption and reimbursement. Hired and leading an experienced medical/clinical team in the US and Europe to execute medical product strategy for all Agendia clinical assays. • Negotiated and closed contracts with managed care organizations bringing the total of covered lives for our tests to >200 million in the US. • Provided medical support in FDA clearance process of Agendia product portfolio, which resulted in two successful 510K FDA clearances. • Managed the filing and maintenance of Agendia's IP portfolio • As part of management raised >$200 million funding.
• Developed global commercial strategy including marketing plan for US launch and a sales plan leading to direct sales presence in US, Netherlands, Italy, France, UK. • Lead Agendia in establishing the US entity in 2008, hired and grew full commercial team. Laid the foundation for growth in the US from $0 to currently $30 million. • Hired and lead European commercial team. Executed a distribution strategy in Europe and Asia, expanded business to 20 more countries. Grew business from $0 to $8 million in Europe. • Lead the organization in the transition from science to clinical utility. Developed global reimbursement strategy resulting in Medicare and private payor reimbursement in the US at reimbursement rate justified by published health economic analysis. • Obtained reimbursement coverage in several European countries. Established first reimbursement for multi-gene assays in Europe, grew reimbursement coverage to >90% in the Netherlands becoming the largest single European market at that time.
• 5th employee, negotiated and closed all contracts, licenses and IP related issues to be able to close our first financing round in 2004. • Played a key role in multiple follow on financing rounds. In total we raised more than $100 million. • Part of negotiation team of the MINDACT trial agreement, a $50 million clinical trial with three Pharma partners, 100 sites, EU sponsored. •Executed two distribution agreements in the US in 2004 and 2007 drove the strategic decision to go direct and to set up US subsidiary. Moved to the US to set up the US commercial organization.
Qameleon Therapeutics brings new oncology drug combinations to the clinic using synthetic lethality screens